Thymus gland disorder

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to…

This early-phase trial tests whether adding the drug acalabrutinib to CAR T-cell therapy can improve treatment for certain B-cell lymphomas. Acalabrutinib blocks cancer growth pathways, while the CAR T-cells are engineered to attack lymphoma cells. The study involves 23 adults an…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…

This study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with …

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This phase II trial tests bintrafusp alfa (M7824) in 9 adults with thymoma or thymic carcinoma that returned after platinum-based chemotherapy. Participants receive the drug intravenously every two weeks until their disease worsens or side effects become intolerable. The study ai…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The m…

This phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers wil…

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…

This early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…

This early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiatio…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This early-phase trial tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The study aims to find the safest dose a…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…

This study was designed to test a combination of two drugs—golcadomide and nivolumab—in people with non-Hodgkin lymphoma whose cancer did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combo could shrink tumors. However, the tri…

This study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…

This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified…

This study tested a combination of two drugs, pembrolizumab and sunitinib, in 9 people with advanced thymic cancer that had spread or could not be removed and had stopped responding to standard chemotherapy. The goal was to see if the combination could shrink tumors or stop them …

This early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This phase 2 trial is testing an injectable form of the immunotherapy drug pembrolizumab (combined with hyaluronidase to help absorption) in 66 adults with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma that has returned or not responded to prior treatmen…

This phase 2 trial is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. The study enrolls 30 patients with various subtypes of the disease. The main g…

This study looks at whether giving a pneumonia vaccine (PCV13) before and after CAR T-cell therapy helps lymphoma patients build stronger immunity. About 26 adults with certain types of B-cell lymphoma will receive the vaccine around their CAR T treatment. The goal is to see if t…

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

This study tests FDA-approved CAR-T cell therapy in 150 children and adults with certain blood cancers that have come back or not responded to treatment. Participants receive their own immune cells that have been reprogrammed to attack cancer cells. The goal is to see how many pa…

This study looks at whether people with a type of lymphoma (primary mediastinal large B-cell lymphoma) can safely avoid radiation therapy after standard chemoimmunotherapy if a PET/CT scan shows no active tumor. About 540 patients who had a negative PET/CT after treatment were ra…

This study tests whether adding an experimental drug called E7777 before standard CAR-T therapy can help people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 30 participants will receive E7777 followed by chemotherapy and a CAR-T produc…

This early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participan…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This study tested whether adding the targeted drug cetuximab to standard chemotherapy could shrink advanced thymoma or thymic carcinoma tumors before surgery. 18 adults with stage II to IVA disease received the combination, then had surgery to remove any remaining tumor. Research…

This study is testing a new robotic surgery system, the da Vinci SP, for removing part or all of a lung (lobectomy) or the thymus gland (thymectomy) in people with lung cancer, benign lung disease, thymoma, or myasthenia gravis. The goal is to see if the robot can perform these s…

This study is testing a therapy where a child's own immune cells are modified in a lab to recognize and attack cancer cells. The treatment is for children with B-cell acute lymphoblastic leukemia or certain types of lymphoma that have come back or not responded to standard treatm…

This early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …

This early-phase trial tests a new drug, loncastuximab tesirine, combined with a standard chemotherapy regimen (DA-EPOCH-R) in 11 adults with aggressive B-cell lymphomas. The main goal is to find the safest dose and check for side effects. It is not yet known if this combination …

This early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…

This early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR …

This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…

This phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…

This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study compares MRI scans to standard CT scans for staging thymoma, a rare chest tumor. Researchers want to see if MRI can detect tumor spread just as well or better, without using radiation. Forty adults with newly diagnosed or recurrent thymoma will undergo both scans befor…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This pilot study tests whether a daily mindful music listening program is practical and acceptable for patients hospitalized after an allogeneic stem cell transplant. About 35 adults will listen to music for one hour each day using a web-based platform. The study measures how fea…

This study looks at whether adding art therapy to physical therapy can help children aged 5 to 18 recover emotionally and physically after a stem cell transplant. For two weeks, some children receive both art and physical therapy daily, while others get only physical therapy. Res…

This study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe …

This study looks at the biology of B-cell lymphoma in children and teens to better understand the disease and long-term effects of treatment. About 128 participants will provide tumor and blood samples for genetic analysis. The goal is not to test a new drug, but to gather knowle…

This study follows 50 young men who had cancer or blood disorders as children and received treatments that can harm fertility. Some stored testicular tissue before treatment; others did not. Researchers will check their fertility through exams, ultrasounds, blood tests, and semen…

This study was designed to see if adding chemotherapy to radiation therapy after incomplete surgery for thymoma or thymic carcinoma could improve survival. It planned to enroll adults aged 18-75 who had incomplete tumor removal. However, the trial was withdrawn before any partici…

This study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…

This study tracks 40 patients with aggressive B-cell lymphoma who have received CAR-T cell therapy. Researchers take a blood sample 7 days after treatment to look for leftover tumor DNA. The goal is to see if they can report results within 3 weeks, giving doctors a head start to …

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…

This research study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. The goal is to analyze these samples to find biological markers that could predict how the disease will progress or which treatments might w…

This study looks at whether a blood test can spot signs of lymphoma coming back after chemotherapy, possibly earlier than regular CT scans. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could …

This study watches 200 people with lung, gut, or hormone diseases over time using special brain scans (PET). It aims to see how these diseases change brain activity and whether those changes can predict tumor return, spread, or survival. No new treatment is tested—just observatio…